Cullinan Therapeutics (CGEM) News Today $8.14 -0.24 (-2.86%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Jump Financial LLC Has $806,000 Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Jump Financial LLC raised its holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 130.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 66,135 shares of the company's stock after buying an additional 37,469 shares durinApril 24 at 4:23 AM | marketbeat.comCullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025April 23 at 10:14 AM | globenewswire.comVoss Capital LP Makes New Investment in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Voss Capital LP bought a new stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 122,361 shares of the company's stock, valued at approximately $1,490,000. Voss Capital LP ownedApril 23 at 6:21 AM | marketbeat.com43,399 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Purchased by XTX Topco LtdXTX Topco Ltd bought a new stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 43,399 shares of the company's stock, valued at approximatApril 22 at 4:15 AM | marketbeat.comWalleye Capital LLC Decreases Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Walleye Capital LLC decreased its position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 52.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 156,497 shares of the company's stock after selliApril 21, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Receives "Buy" Rating from HC WainwrightApril 19, 2025 | americanbankingnews.comCullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in ...April 18, 2025 | seekingalpha.comCullinan Therapeutics' (CGEM) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $33.00 price objective on shares of Cullinan Therapeutics in a report on Wednesday.April 18, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Hyperfine (HYPR) and Cullinan Management (CGEM)April 17, 2025 | markets.businessinsider.comCullinan receives approval from EMA to initiate Phase 1 trial of CLN-978April 17, 2025 | markets.businessinsider.comKennedy Capital Management LLC Invests $1.35 Million in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Kennedy Capital Management LLC acquired a new position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 111,049 sApril 17, 2025 | marketbeat.comCullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid ArthritisApril 16, 2025 | globenewswire.comVanguard Group Inc. Reduces Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Vanguard Group Inc. cut its stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 2.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,936,227 shares of the company's stock after selliApril 15, 2025 | marketbeat.comCenterBook Partners LP Reduces Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)CenterBook Partners LP trimmed its stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 85.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,987 shares of the company's stock after sellinApril 14, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Holdings Lifted by Alliancebernstein L.P.Alliancebernstein L.P. lifted its holdings in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 8.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,011,525 shares of the company's stock afteApril 9, 2025 | marketbeat.comCullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b DataApril 8, 2025 | seekingalpha.comSpringhill Fund Asset Management HK Co Ltd Purchases New Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Springhill Fund Asset Management HK Co Ltd acquired a new position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 276,400 shares oApril 8, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of "Buy" from AnalystsCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) has earned a consensus recommendation of "Buy" from the eight analysts that are covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that havApril 3, 2025 | marketbeat.comBIT Capital GmbH Takes Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)BIT Capital GmbH bought a new position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 94,344 shares of the company's stock, valuMarch 28, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Trading Down 2.1% - Should You Sell?Cullinan Therapeutics (NASDAQ:CGEM) Trading Down 2.1% - Here's What HappenedMarch 15, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Earns "Overweight" Rating from Morgan StanleyMorgan Stanley reissued an "overweight" rating and set a $35.00 price target (down from $38.00) on shares of Cullinan Therapeutics in a research note on Friday.March 8, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Recommendation of "Buy" from AnalystsShares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight analysts that are presently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average 1 year pricMarch 8, 2025 | marketbeat.comCullinan Therapeutics assumed with an Overweight at Morgan StanleyMarch 7, 2025 | markets.businessinsider.comCullinan Therapeutics (CGEM) to Release Quarterly Earnings on ThursdayCullinan Therapeutics (NASDAQ:CGEM) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 6, 2025 | marketbeat.comFY2029 Earnings Forecast for CGEM Issued By WedbushCullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Analysts at Wedbush issued their FY2029 earnings estimates for shares of Cullinan Therapeutics in a research report issued on Thursday, February 27th. Wedbush analyst R. Driscoll expects that the company will earn ($2.22) per share for theMarch 3, 2025 | marketbeat.comQ1 Earnings Estimate for CGEM Issued By William BlairCullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Cullinan Therapeutics in a note issued to investors on Thursday, February 27th. William Blair analyst M. Phipps forecasts that the company will postMarch 3, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Cullinan Therapeutics (NASDAQ:CGEM)HC Wainwright reaffirmed a "buy" rating and set a $33.00 target price on shares of Cullinan Therapeutics in a research note on Friday.March 1, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells $41,754.35 in StockCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jeffrey Alan Jones sold 4,895 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $8.53, for a total value of $41,754.35. Following the transaction, the insider now directly owns 174,164 shares in the company, valued at approximately $1,485,618.92. This represents a 2.73 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.February 28, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) CEO Nadim Ahmed Sells 12,529 SharesCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) CEO Nadim Ahmed sold 12,529 shares of the business's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $8.53, for a total transaction of $106,872.37. Following the completion of the transaction, the chief executive officer now owns 430,621 shares of the company's stock, valued at approximately $3,673,197.13. This trade represents a 2.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.February 28, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Announces Earnings ResultsCullinan Therapeutics (NASDAQ:CGEM - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.02.February 28, 2025 | marketbeat.comInsider Selling: Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells 4,895 Shares of StockFebruary 28, 2025 | insidertrades.comCullinan Therapeutics: Q4 Earnings SnapshotFebruary 27, 2025 | sfgate.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Cullinan Management (CGEM)February 27, 2025 | markets.businessinsider.comCullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 27, 2025 | globenewswire.comCullinan Therapeutics (NASDAQ:CGEM) Sets New 52-Week Low - Should You Sell?Cullinan Therapeutics (NASDAQ:CGEM) Hits New 12-Month Low - Here's What HappenedFebruary 24, 2025 | marketbeat.comCullinan Therapeutics to Participate in Upcoming Investor ConferencesFebruary 24, 2025 | globenewswire.comCullinan Therapeutics (NASDAQ:CGEM) Reaches New 52-Week Low - Time to Sell?Cullinan Therapeutics (NASDAQ:CGEM) Hits New 12-Month Low - Here's WhyFebruary 19, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Short Interest UpdateCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) saw a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 8,730,000 shares, a drop of 10.7% from the January 15th total of 9,780,000 shares. Currently, 23.7% of the shares of the company are short sold. Based on an average trading volume of 555,600 shares, the days-to-cover ratio is currently 15.7 days.February 19, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Reaches New 12-Month Low - What's Next?Cullinan Therapeutics (NASDAQ:CGEM) Hits New 52-Week Low - Here's WhyFebruary 12, 2025 | marketbeat.comCullinan Therapeutics Inc.February 12, 2025 | wsj.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of "Buy" by BrokeragesShares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) have received a consensus rating of "Buy" from the seven brokerages that are covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12 month pFebruary 11, 2025 | marketbeat.comLeerink Partnrs Has Strong Estimate for CGEM FY2024 EarningsCullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Leerink Partnrs upped their FY2024 earnings per share (EPS) estimates for Cullinan Therapeutics in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now expects that the company will earn ($2.88) per shFebruary 10, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for CGEM Q1 Earnings?Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Cullinan Therapeutics in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the compFebruary 7, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Sees Strong Trading Volume - What's Next?Cullinan Therapeutics (NASDAQ:CGEM) Sees Unusually-High Trading Volume - Here's What HappenedFebruary 6, 2025 | marketbeat.comHC Wainwright Brokers Decrease Earnings Estimates for CGEMCullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Research analysts at HC Wainwright lowered their FY2025 earnings estimates for Cullinan Therapeutics in a report released on Wednesday, January 29th. HC Wainwright analyst E. White now anticipates that the company will post earnings of ($2February 3, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth PlansJanuary 31, 2025 | finance.yahoo.comWhat is HC Wainwright's Estimate for CGEM Q1 Earnings?Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Cullinan Therapeutics in a research report issued on Wednesday, January 29th. HC Wainwright analyst E. White anticipates that the company will postJanuary 31, 2025 | marketbeat.comCullinan Management (CGEM) Receives a Buy from BTIGJanuary 30, 2025 | markets.businessinsider.comCullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech ConferenceJanuary 30, 2025 | finance.yahoo.comCullinan Management Receives ‘Buy’ Rating as Phase 2b Study Success and Taiho Partnership Boost ProspectsJanuary 29, 2025 | markets.businessinsider.com Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEM Media Mentions By Week CGEM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGEM News Sentiment▼1.060.72▲Average Medical News Sentiment CGEM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGEM Articles This Week▼83▲CGEM Articles Average Week Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TARS News BEAM News NAMS News KYMR News BLTE News BHC News JANX News AAPG News ARWR News HRMY News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGEM) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
